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Elevated Baseline C-Reactive Protein as a Predictor
of Outcome After Aneurysmal Subarachnoid
Hemorrhage: Data From the Simvastatin in
Aneurysmal Subarachnoid Hemorrhage
(STASH) Trial
BACKGROUND: There remains a proportion of patients with unfavorable outcomes
after aneurysmal subarachnoid hemorrhage, of particular relevance in those who
present with a good clinical grade. A forewarning of those at risk provides an oppor-
tunity towards more intensive monitoring, investigation, and prophylactic treatment
prior to the clinical manifestation of advancing cerebral injury.
OBJECTIVE: To assess whether biochemical markers sampled in the first days after the
initial hemorrhage can predict poor outcome.
METHODS: All patients recruited to the multicenter Simvastatin in Aneurysmal Hem-
orrhage Trial (STASH) were included. Baseline biochemical profiles were taken between
time of ictus and day 4 post ictus. The t-test compared outcomes, and a backwards
stepwise binary logistic regression was used to determine the factors providing inde-
pendent prediction of an unfavorable outcome.
RESULTS: Baseline biochemical data were obtained in approximately 91% of cases
from 803 patients. On admission, 73% of patients were good grade (World Federation of
Neurological Surgeons grades 1 or 2); however, 84% had a Fisher grade 3 or 4 on
computed tomographic scan. For patients presenting with good grade on admission,
higher levels of C-reactive protein, glucose, and white blood cells and lower levels of
hematocrit, albumin, and hemoglobin were associated with poor outcome at discharge.
C-reactive protein was found to be an independent predictor of outcome for patients
presenting in good grade.
CONCLUSION: Early recording of C-reactive protein may prove useful in detecting those
good grade patients who are at greater risk of clinical deterioration and poor outcome.
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S
ubarachnoid hemorrhage (SAH) from
a ruptured intracranial aneurysm affects
approximately 600 000 patients worldwide1
and 7000 patients within the United Kingdom2
each year. Despite considerable advances in
treatment, the condition is associated with
a disproportionate (25%) loss of productive
life and cost to society affecting a young age
group.3 Combined morbidity and mortality
reach 50%, with one-third of survivors becom-
ing dependent.4
Late clinical deterioration is associated with
morbidity and mortality, the causes of which are
multifactorial. The most recognized contributor
to clinical deterioration and unfavorable outcome
is delayed cerebral ischemia. Although phase II
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randomized controlled trials suggested a potential role for statin
therapy in SAH,5-8 a large placebo-controlled and blinded phase
III study showed no benefit for simvastatin 40 mg in either the
long-term or short-term outcome of patients with aneurysmal
subarachnoid hemorrhage (STASH Trial).9
In addition to delayed cerebral ischemia, there are a number of
non-neurological systemic complications that often occur post
SAH and which can contribute to poor outcome, including sepsis,
anemia, hypertension, hypotension, hyperglycemia, hypernatre-
mia, hyponatremia, hypomagnesemia, and cardiac complica-
tions.2,10 Many of these complications could be attributed to
poor neurological status on admission. However, there remains
a group of patients who present with a good World Federation of
Neurological Surgeons (WFNS) grade who unpredictably dete-
riorate with a poor outcome. In this group there is a need for early
recognition and close monitoring, opening up the opportunity to
earlier intervention.
In a post hoc study of the STASH data, we explored whether
biochemical markers sampled soon after the time of initial
hemorrhage are predictive of a subsequent poor outcome, hence
providing a simple and readily accessible indication of who in the
population of good grade SAH patients are likely to worsen.
METHODS
Study Population
Patients were recruited from 35 neurosurgical units (23 in the United
Kingdom and 12 non-United Kingdom sites) between 2007 and 2013.9
Laboratory data were extracted from the STASH database. Approval for
the study was granted by the Berkshire Research Ethics Committee (06/
MRE12/26) and the Medicine and Healthcare products Regulatory
Agency, MHRA (2006-000277-30). Appropriate ethics and regulatory
approvals were obtained for all participating sites not in the United
Kingdom in accordance with the International Conference on Harmo-
nisation guidelines for good clinical practice (ICH GCP). Written
informed consent was obtained from all patients or their legal
representative. The study conformed to CONSORT guidelines (trial
profile in Simvastatin in aneurysmal subarachnoid hemorrhage [STASH]
publication9).
Inclusion criteria were radiological confirmatory evidence of an SAH,
age 18 to 65 years, and presentation less than 96 hours from ictus.
Exclusion criteria were patient taking statin therapy at presentation,
pregnancy, no reasonable prospect of survival, known renal or hepatic
impairment, patient not fully independent before bleed, strong suspicion
of drug or alcohol misuse, patient unlikely to be amenable to follow-up,
patient taking warfarin-type drugs or contraindicated medications or
suspected additional life-threatening disease.
Baseline Data
Baseline data included age, sex, ethnic origin, and WFNS grade on
presentation to the neurosurgical unit. Radiological data included Fisher
grade on computed tomography (CT), presence of intraparenchymal or
intraventricular bleed, presence of hydrocephalus (requiring external
ventricular drainage [EVD]), and aneurysm location. The Fisher grading
was determined as described in the original publication,9 in conjunction
with a radiologist at each local participating site, after review of the
imaging. The extent of intracerebral or intraventricular involvement was
not prescriptive; however, it was assumed to be diagnostic of grade 4.
Laboratory Tests
All patients had biochemical profiles taken at trial entry, prior to
randomization (baseline values) and again between days 9 to 12 post
randomization (late values). Recorded parameters were liver function:
C-reactive protein (CRP), bilirubin, alanine aminotransferase (ALT),
alkaline phosphatase (ALP), albumin, glucose, and magnesium; kidney
function: creatine kinase (CK), sodium and potassium; lipid profile: total
cholesterol, low-density lipoprotein, high-density lipoprotein and trigly-
cerides; and blood profile: hematocrit, hemoglobin, WBC (white blood
cells) and platelets and fibrinogen. Patients who were discharged prior to
day 9 did not receive a second biochemical profile. Suspected adverse
events were reviewed on an individual patient basis.
Outcome Measure
Themodified Rankin Scale (mRS) was dichotomized to good (mRS 0-2)
and poor outcome (mRS 3-6) at discharge and again at 6 months post ictus.
The scale was in the formof a simplified questionnaire whichwas assessed by
a clinician at outcome and by postal questionnaire at 6 months, which was
verified using the Lindsay Wilson structured questionnaire.
Statistical Analysis
All analyses were on an intention-to-treat basis. Data were presented as
mean6 standard deviation and 95% confidence interval. Analyses were
performed using SPSS statistical software (IBM Corporation, Armonk,
New York). The t-test was used to compare the biochemical markers
between outcome groups. The biochemical parameters that reached
significance along with recognized clinical factors known to affect outcome
were assessed using a backwards likelihood ratio (LR) stepwise multivari-
able binary logistic regression to determine independent predictors of
unfavorable outcome at discharge and at 6 months. The odds ratio was
calculated and presented with 95% CI. P values less than 0.05 were
considered to be statistically significant.
RESULTS
Demographics
Data from 803 patients are outlined in Table 1. For the study,
2066 patients did not meet the entry criteria; the major exclusions
were age (over 65 years), taking statin therapy at presentation, and
time from ictus to admission.96 hours. The majority of patients
were good grade on admission (WFNS grades 1 or 2, 588 out of
803 patients, 73%); however, 84% (673 out of 803) had a Fisher
grade 3 or 4 on a CT scan.
Observational Sample Data
Baseline biochemical data were obtained in approximately 91%
of cases (Table 2). The mean time from ictus to randomization
was 2.1 days (SD 1.0). Table 3 shows the mean values of the
baseline biochemical parameters for patients who were classified
as good outcome (mRS 1-2) vs poor outcome (mRS 3-6) at
discharge. Baseline measures of CRP, CK, sodium, potassium,
glucose, magnesium, and WBC showed elevated levels in patients
with poor outcome compared to good outcome at discharge.
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Likewise, lower levels of bilirubin and albumin were associated
with poor outcome. For those patients presenting with good
grade on admission (Table 4), higher baseline levels of CRP,
glucose, and WBC and lower levels of hematocrit, albumin, and
hemoglobin were the biochemical measures associated with an
eventual poor outcome.
The mean CRP levels for good grade patients categorized by
outcome and grouped by post-ictal day are shown in Table 5. For
the good outcome group, the values were 12.25 mg/L and 20.95
mg/L on post-ictal day 1 and 3, respectively. The corresponding
values for patients with poor outcome were 32.55 mg/L and 42.84
mg/L. The difference in these values was highly significant on
days 1, 2, and 3, but not day 4 post ictus (P = .003, 0.01, 0.002,
and 0.30, respectively).
Regression Analysis
Binary logistic regression identified baseline CRP, potassium,
glucose, and WBC to be independently related to poor outcome at
discharge, along with age, WFNS status, and Fisher CT grading on
admission (Table 6). Other imaging parameters related to the
magnitude of the bleed such as intraventricular and intraparen-
chymal hemorrhage were not found to be predictive of outcome.
Importantly, when only patients presenting with WFNS 1 and 2
were analyzed, only baseline CRP was found to be an independent
biochemical predictor of outcome (Table 7).
An additional multivariate model was applied, including sepsis,
statin and placebo, white cell count, and CRP on day 9, to
TABLE 2. Baseline Biochemical Dataa
n Range Mean (SD)
CRP, mg/L 753 1.00-492.00 38.20 (53.86)
Bilirubin, mmol/L 773 2.00-46.00 10.41 (5.32)
ALP, U/L 770 4.00-377.00 68.70 (31.08)
ALT, U/L 766 5.00-289.00 24.84 (23.17)
Creatinine kinase, U/L 698 2.00-5621.00 254.73 (425.96)
Albumin, g/L 765 16.00-53.00 34.99 (0.20)
Sodium, mmol/L 794 118.00-184.00 140.00 (4.75)
Potassium, mmol/L 792 3.20-6.20 3.85 (0.45)
Glucose, mmol/L 673 2.48-18.60 6.67 (1.88)
Magnesium, mmol/L 733 0.18-1.94 0.85 (0.17)
Hematocrit, L/L 775 0.10-0.85 0.36 (0.004)
Hemoglobin, g/dL 793 4.30-17.30 12.20 (1.7)
WBC, 109/L 793 4.30-27.90 12.20 (3.88)
Platelets, 109/L 792 38.00-544.0 231.68 (65.66)
Fibrinogen, G/L 349 1.05-9.0 4.03 (1.20)
aALP, alkaline phosphatase; ALT, alanine aminotransferase; CRP, C-reactive protein;
SD, standard deviation; WBC, white blood cells.
TABLE 1. Baseline Patient Characteristicsa
n = 803 (%)
UK recruits 676 (84)
Non-UK recruits 127 (16)
Age mean (range) y, SD 50 (20-69) y, 9.709
Sex
Male 252 (31)
Female 551 (69)
Race
White 723 (90)
Asian 37 (5)
Black 13 (2)
Hispanic 24 (3)
Other 5 (,1)
WFNS grade
1 390 (49)
2 198 (25)
3 31 (4)
4 107 (13)
5 77 (10)
Motor deficit 98 (12)
Cranial nerve deficit 71 (9)
Ventilated 165 (21)
Fisher grade
1 15 (2)
2 111 (14)
3 267 (33)
4 406 (51)
Intraparenchymal hemorrhage 53 (14)
Intraventricular hemorrhage 136 (35)
Subdural hemorrhage 8 (2)
Cerebral infarct 3 (,1)
Hydrocephalus (requiring EVD) 55 (14)
aEVD, external ventricular drainage; SD, standard deviation; UK, United Kingdom,
WFNS, World Federation of Neurological Surgeons.
TABLE 3. Mean Values of Baseline Biochemical Parameters
Determined by mRS at Dischargea
mRS 0-2,
Mean (SD)
mRS 3-6,
Mean (SD) P Value
CRP, mg/L 23.33 (37.42) 60.57 (65.78) ,.001
Bilirubin, umol/L 10.88 (5.80) 9.69 (4.41) .02
ALP, U/L 69.54 (32.55) 67.54 (28.64) .84
ALT, U/L 24.15 (23.29) 25.84 (23.02) .33
Creatinine kinase, U/L 203.24 (317.56) 331.59 (540.98) ,.001
Albumin, g/L 36.25 (4.94) 33.10 (5.75) .003
Sodium, mmol/L 139.58 (4.12) 140.87 (5.51) ,.001
Potassium, mmol/L 3.79 (0.41) 3.95 (0.48) .01
Glucose, mmol/L 6.31 (1.69) 7.20 (2.01) .002
Magnesium, mmol/L 0.84 (0.12) 0.88 (0.20) ,.001
Hematocrit, L/L 0.37 (0.07) 0.35 (0.49) .28
Hemoglobin, g/dL 12.42 (1.65) 11.78 (1.70) .82
WBC, 109/L 11.56 (3.40) 13.19 (4.35) ,.001
Platelets, 109/L 234.56 (63.27) 226.73 (70.53) .07
Fibrinogen, G/L 3.86 (1.13) 4.30 (1.25) .15
aALP, alkaline phosphatase; ALT, alanine aminotransferase; CRP, C-reactive protein;
mRS, modified Rankin Scale; SD, standard deviation; WBC, white blood cells.
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determine whether elevated CRP is related to outcome independent
of infection and sepsis.We foundbaselineCRP (odd ratio [OR]1.02;
95% CI 1.01-1.02; P = .002) to be an independent predictor of
outcome at discharge. This was not the case for late day 9 CRP
values (OR 1.00; 95% CI 1.00-1.01; P = .053). Statins showed no
significant effect on CRP (mean day 9 CRP in statin group, 33.67
mg/L and in the placebo group 31.76 mg/L, P = .64).
For clinical outcome at 6 months, CRP remained an indepen-
dent predictor for all patients, but not for good grade patients alone
(Tables 8 and 9).
Defining CRP Thresholds
To select an arbitrary CRP threshold for outcome prediction,
receiver operating characteristic (ROC) curve analysis determined
sensitivity and specificity for each epoch post ictus (Figure).
Patients who had samples taken within 24 hours of ictus and on
day 4 post ictus were omitted from the ROC curve analysis, as the
numbers in these groups were small (11 and 56, respectively).
Table 10 shows the corresponding values for baseline CRP in
each epoch with the associated predictive sensitivity and
specificity values. For example, a baseline CRP level of 17.5
mg/L on day 1 post ictus would predict poor outcome at
discharge with a confidence level of 58% sensitivity and 79%
specificity, whereas on day 3 post ictus, a threshold of 20.5 mg/L
would predict poor outcome with a confidence level of 65%
sensitivity and 68% specificity.
DISCUSSION
While the outcomes after SAH have significantly improved
during the past 2 decades, the condition is still associated with
relatively high levels of mortality and morbidity.11,12 Providing
a simple and reliable method for earlier prediction of clinical
deterioration, particularly in good grade patients, would have
a significant bearing on targeted escalation of observation and
therapy.
In this study, using data from the STASH trial, we have
identified a number of biochemical parameters that showed
differences in patients achieving favorable vs unfavorable outcome.
Of these, CRP remained the dominant independent variable
associated with poor outcome at discharge, independently of age,
WFNS grade, and the Fisher grade. Because CRP is a sensitive
marker of a systemic inflammatory reaction,13,14 this observation
has a common and partly understood pathophysiological basis.
Inflammation is regarded to be an important factor influencing
outcome after aneurysmal SAH and has been demonstrated to
play a role in early brain injury after SAH.15 Although elevated
baseline CRP in relation to poor outcome after an SAH has been
previously documented,16-20 the relevance of an elevated baseline
CRP on outcome in good grade patients has not been previously
demonstrated.
We recognize that there are numerous potential explanations for
increased CRP after SAH, most notably development of sepsis,
which is known to adversely influence outcome. In the present study
we aimed to analyze the admission parameters at a time point where
TABLE 4. Mean Values of Baseline Biochemical Parameters
Determined by mRS at Discharge: WFNS 1 and 2 on Admissiona
mRS 0-2,
Mean (SD)
mRS 3-6,
Mean (SD) P Value
CRP, mg/L 18.50 (29.84) 39.59 (48.69) ,.001
Bilirubin, umol/L 10.89 (5.80) 10.07 (4.75) .10
ALP, U/L 69.82 (32.39) 65.97 (27.07) .16
ALT, U/L 24.24 (24.34) 23.24 (16.34) .58
Creatinine kinase, U/L 175.24 (286.89) 226.93 (323.15) .09
Albumin, g/L 36.53 (4.92) 35.38 (5.08) .02
Sodium, mmol/L 139.39 (3.91) 139.41 (4.41) .96
Potassium, mmol/L 3.79 (0.40) 3.87 (0.46) .06
Glucose, mmol/L 6.26 (1.68) 6.76 (1.68) .004
Magnesium, mmol/L 0.84 (0.13) 0.84 (0.15) .66
Hematocrit, L/L 0.37 (0.07) 0.36 (0.50) .003
Hemoglobin, g/dL 12.51 (1.65) 12.16 (1.60) .03
WBC, 109/L 11.39 (3.34) 12.38 (3.98) .003
Platelets, 109/L 237.62 (61.72) 241.24 (70.01) .58
Fibrinogen, G/L 3.85 (1.11) 4.05 (1.00) .15
aALP, alkaline phosphatase; ALT, alanine aminotransferase; CRP, C-reactive protein;
mRS, modified Rankin Scale; SD, standard deviation; WBC, white blood cells; WFNS,
World Federation of Neurological Surgeons.
TABLE 5. CRP Values at Baseline for Patients WFNS 1 to 2 on Admissiona
Ictus to Baseline CRP Day 0 Day 1 Day 2 Day 3 Day 4
mRS 1-2 at discharge
No. of patients 8 99 140 115 42
Mean CRP, mg/L (SD) 11.12 (4.88) 12.25 (17.01) 17.01 (22.28) 20.95 (24.97) 32.83 (65.58)
mRS 3-6 at discharge
No. of patients 3 31 52 43 14
Mean CRP, mg/L (SD) 10.00 (5.12) 32.55 (34.04) 39.90 (52.66) 42.84 (41.12) 59.14 (84.12)
P Value 0.003 0.007 0.002 0.299
aCRP, C-reactive protein; mRS, modified Rankin Scale; SD, standard deviation; WFNS, World Federation of Neurological Surgeons.
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infection is unlikely to be present. When assessed in a multivariate
model, baseline CRP and sepsis were both independent predictors
of outcome. Furthermore, a continuous rise in CRP on consecutive
days after SAH was seen in both the good as well as the poor
outcome groups, suggesting that a systemic inflammatory response
is playing an active part independently of sepsis.
The actual time-from-ictus to baseline sampling ranged from
,24 hours (day 0) to 96 hours (day 4) post ictus. This is in
contrast to previous studies such as Juvela et al20 where CRP
values were obtained within 48 hours of ictus or Romero et al19
where CRP values were obtained ,24 hours post ictus. These
time epochs explain the differences in absolute values of CRP
recorded in the respective studies. We have not included later
(post day 4) CRP values in this analysis, as our objective was to
identify early biochemical markers. Furthermore, later samples
are more likely to be contaminated by evolving sepsis.
We examined ROC curves to determine a clinical baseline CRP
threshold as a predictor of poor outcome. As expected, selecting
higher baseline CRP thresholds caused a decrease in sensitivity and
increase in specificity; however, the sensitivity range at each time
interval was not consistent. The likelihood of predicting poor
outcome at most CRP levels seemed to have higher sensitivity on
day 1 and day 3 when compared to day 2, no doubt a reflection of
the relatively small numbers in each epoch.
The presented data suggest that an elevated baseline CRP was
both an early and an independent predictor of outcome. Impor-
tantly, this observation was apparent when only the good grade
patients were analyzed. This suggests that the observed inflamma-
tory response was not only a reflection of the severity of the initial
ictus determining presentation grade, but also of a potentially
progressive condition in good grade patients. Larger numbers with
consistent timing in CRP evaluation is required to identify a more
definitive level of CRP that predicts deterioration in the early stage
post hemorrhage.Clearly, the earlier themeasurable rise inCRP, the
more likely it will serve as a valuable predictor, allowing time for
intervention. On that note, we are encouraged that rises in CRP
were seen so early after the initial ictus.
As these data was derived from the STASH trial,9 we included
the potential effect of statin therapy on the measured parameters.
Statins had no influence, and given that the trial drug was started
after the baseline blood samples were taken, these tests were not
contaminated by any theoretical statin effect.
A number of publications describe the role of biomarkers as
a precursor to clinical deterioration after a subarachnoidhemorrhage.
However, their role is unclear. Lad et al21 reviewed 27 articles in
TABLE 6. Binary Logistic Regression Model of Baseline Parameters
for Determining Poor Outcome at Discharge: All Patientsa
P Value OR 95% CI
Age (y) ,.001 1.049 1.026-1.073
WFNS (grade) ,.001 1.632 1.363-1.953
Fisher (grade) .001 1.709 1.249-2.338
CRP (mg/L) .03 1.005 1.000-1.010
Bilirubin (umol/L) .07 0.961 0.920-1.003
Albumin (g/L) .06 0.959 0.918-1.002
Potassium (mmol/L) .004 2.017 1.249-3.258
Glucose (mmol/L) .05 1.133 1.002-1.282
WBC (109/L) .03 1.065 1.007-1.127
aCI, confidence interval; CRP, C-reactive protein; OR, odds ratio; WBC, white blood
cells; WFNS, World Federation of Neurological Surgeons.
TABLE 7. Binary Logistic Regression Model of Baseline
Biochemical Markers for Determining Poor Outcome at Discharge:
WFNS Grade 1 to 2 on Admissiona
P Value OR 95% CI
Age (y) .004 1.039 1.012-1.065
Fisher (grade) .002 1.701 1.208-2.396
CRP (mg/L) ,.001 1.014 1.007-1.022
Bilirubin (umol/L) .108 0.961 0.915-1.009
Potassium (mmol/L) .07 1.722 0.965-3.074
WBC (109/L) .08 1.061 0.993-1.133
aCI, confidence interval; CRP, C-reactive protein; OR, odds ratio; WBC, white blood
cells.
WFNS removed from regression model as only good grade patients were
analyzed.
TABLE 8. Binary Logistic Regression Model of Baseline
Biochemical Markers for Determining Poor Outcome at 6 Months:
All Patientsa
P Value OR 95% CI
Age (y) .08 1.027 1.005-1.049
WFNS (grade) ,.001 1.519 1.299-1.775
Fisher (grade) .02 1.497 1.077-2.080
CRP (mg/L) .04 1.004 1.000-1.008
WBC (109/L) .003 1.082 1.027-1.140
aCI, confidence interval; CRP, C-reactive protein; OR, odds ratio; WBC, white blood
cells; WFNS, World Federation of Neurological Surgeons.
TABLE 9. Binary Logistic Regression Model of Baseline
Biochemical Markers for Determining Poor Outcome at 6 Months:
WFNS Grade 1 to 2 on Admissiona
P Value OR 95% CI
Age (y) .007 1.032 1.004-1.061
Fisher (grade) .02 1.523 1.063-2.180
WBC (109/L) .001 1.120 1.047-1.198
aCI, confidence interval; OR, odds ratio; WBC, white blood cells; WFNS, World
Federation of Neurological Surgeons.
WFNS removed from regression model as only good grade patients were analyzed.
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relation to a number of potential markers, none of which have been
established as a biomarker for diagnosing preclinical vasospasm or
monitoring its progression. In contrast to our findings, McMahon
et al22 determined the incidence of raised biomarkers including
IL-6 and CRP as a precursor to cerebral vasospasm. They analyzed
samples up to 13 days post angiography and found an elevation in
interleukin-6 but not CRP reflected impending cerebral ischemia;
however, their endpoint was delayed cerebral ischemia, not
outcome, and the numbers were relatively small.
Limitations
A limitation of this study is that the data presented were the result
of a post hoc analysis. However, the results imply that prospective
early recording of CRP may prove useful in detecting those good
grade patients who are at an increased risk of clinical deterioration.
If verified, besides providing an obvious clinical utility, identification
of patients at risk of deterioration using earlymeasures of CRP could
prove useful in the design of clinical trials in SAH. Another
limitation is the timing of the outcomemeasure. It is well recognized
that patients improve their outcome score between discharge and 6
months; hence, any early treatment gain is diluted. Thismay explain
why baseline CRPwas only predictive of outcome in the good grade
patients at discharge. Earlymeasures of clinical well-beingmay prove
a more useful way to measure outcomes in studies of this type,
affording the opportunity of demonstrating influences on speed of
recovery, need for rehabilitation, and time to discharge home.
CONCLUSION
The post hoc analysis of biochemical data derived from the
STASH study has shown that baseline CRP levels may have
predictive value in identifying good grade patient who are at
greater risk of a clinical deterioration. A targeted prospective study
is required to validate and quantify this observation.
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should be used to reveal prognostic factors for outcome as well as for
knowledge of pathophysiological mechanisms of clinical deterioration.
Common inexpensive laboratory markers that are in routine clinical use
may be more beneficial than expensive methods without validation.
C-reactive protein (CRP) is an acute phase sensitive, nonspecific
inflammatory marker and initiating factor of inflammation and infection.
Previous large studies including meta-analyses indicate that elevated CRP
levels increase modestly and independent of confounding factors risk for
coronary heart disease as well as for both vascular and nonvascular mor-
tality.1,2 CRP levels also predict risk for ischemic stroke, but no more
after adjustment for risk factors (hypertension, cigarette smoking, dia-
betes, and heart disease), as CRP levels correlate with these risk factors.2
Elevated CRP values seen within 2 days after bleeding correlate with
outcome, but do not seem to predict delayed cerebral ischemia or
infarction after SAH.3,4 Similar correlation between CRP levels obtained
within 24 hours after primary intracerebral hemorrhage and outcome has
been observed.5 These associations have been independent of clinical and
radiological severity of bleeding and of prehemorrhage confounding
factors (hypertension, cigarette smoking, diabetes, and heart disease).
Prognostic value of CRP levels obtained later than 3 to 4 days after
bleeding decreases significantly because the levels are affected by severity
of clinical symptoms and infections (sepsis and pneumonia).
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T he authors present a post hoc analysis of the STASH trial data toidentify biomarkers that could be predictive of poor outcome among
patients with favorable grade aneurysmal subarachnoid hemorrhage.
This study identified elevations in C-reactive protein (CRP) to be
associated with poor outcome after subarachnoid hemorrhage. Although
CRP has also been identified as an important biomarker by other recent
studies,1-3 the authors are to be congratulated for further demon-
strating this association, specifically among patients with favorable
grade hemorrhages. Using biomarkers to identify patients with an
increased likelihood of poor outcome is a worthwhile pursuit, but this
information will be especially useful among patients that would oth-
erwise be expected to progress well, based on having a small volume of
blood on computed tomographic imaging. This study will also be
useful in the drafting of future aneurysmal hemorrhage biomarker
studies, which might further validate these results through a pro-
spective design.
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